Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The commonplace expression of the ROS1 oncogene in meningiomas suggests a role for this oncogene in the etiology of these tumors.
|
7553586 |
1995 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis yielded 20 novel genes differentially expressed in both lung adenomas and ACs versus normal lungs, including the tumor suppressor APC2 and the oncogene Ros 1.
|
14647414 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We identified and characterized the c-ROS gene promoter region and report that the ectopic expression of c-ROS in tumors is tied to hypomethylation of a CpG island in the c-ROS promoter.
|
19276365 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently endogenous ROS generation in DU-145 tumor spheroids was increased in the presence of either IA or 2-DDG, which was abolished upon coincubation with ebselen.
|
19950199 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Some of the ALK and ROS1 rearranged tumors may also harbor coexisting EGFR mutations.
|
22661537 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In recurred NSCLC, ROS1 expression was significantly higher in recurring tumors (38%) than primary tumors (19%).
|
22915320 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ROS1 inhibition may be an effective treatment strategy for the subset of patients with NSCLC whose tumors express ROS1 fusion genes.
|
22919003 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Crizotinib has recently been shown to be an effective ROS1 inhibitor in ROS1-rearranged NSCLC, with potential future clinical applications in ROS1-rearranged tumors.
|
22989574 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty-three tumor samples were ROS1 IHC-positive.
|
23400546 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence in situ hybridization using ROS1 break-apart probes revealed positive rearrangement signals in 23% to 93% of the tumor cells in ROS1 fusion-positive cancers, which were readily distinguished using a 15% cutoff value from 50 ROS1 fusion-negative tumors tested, which showed 0% to 6% rearrangement signals.
|
23426121 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, it was reported that ROS1 expression was observed in diverse cancer tissue or cell lines and ROS1 is associated with the development of several tumors.
|
23549810 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On retesting the patient's tumor sample was found to harbor a ROS1-translocation.
|
23558310 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting ROS1 fusion proteins with the small-molecule inhibitor crizotinib is showing promise as an effective therapy in patients with NSCLC whose tumors are positive for these genetic abnormalities.
|
23719267 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We performed a biopsy of a resistant tumor and identified an acquired mutation leading to a glycine-to-arginine substitution at codon 2032 in the ROS1 kinase domain.
|
23724914 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ROS1 protein expression in tumor cells is 100% sensitive and 92% specific for ROS1 rearrangements by FISH.
|
23887156 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of lung cancers has raised significant clinical interest because small molecule inhibitors may be effective to these tumors.
|
24186139 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Then, we confirmed antitumorigenic effects of TA in a nude mouse orthotopic ATC model, and this result accompanied the augmentation of NAG-1 expression and ROS generation in tumor tissue.
|
24216474 |
2014 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The concept of using information from a patient's tumor to make therapeutic and treatment decisions has revolutionized the landscape for cancer care and research in general.Management of non-small-cell lung cancer, in particular, has seen several of these advances, with the understanding of activating mutations in EGFR, fusion genes involving ALK, rearrangements in ROS-1, and ongoing research in targeted therapies for K-RAS and MET.
|
24292963 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, eIF2αP-deficient human tumor cells are highly susceptible to extrinsic ROS generated by the pro-oxidant drug doxorubicin by undergoing premature senescence.
|
24334569 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To accomplish this, we analyzed tumor samples from a patient who initially responded to the ROS1 inhibitor crizotinib but eventually developed acquired resistance.
|
24349229 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Considering a positivity threshold of 2+ stained cells, the sensitivity of the ROS1 D4D6 antibody compared to FISH was 100% and the specificity 96.9%, as two HER2-mutated tumors were positive with D4D6 antibody, without any translocation in FISH.
|
24380695 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified seven ROS1 and 14 RET fusion-positive tumors and confirmed the fusion status by RT-PCR and FISH.
|
24418728 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors with ROS1 fusions had significantly larger diameter than ROS1 fusion-negative tumors (P = 0.007), whereas all the 15 tumors harboring RET fusions were ≤ 3 cm in diameter (P = 0.001).
|
24629636 |
2014 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Archival formalin-fixed, paraffin-embedded (FFPE) tumor specimens were collected from advanced NSCLC patients enrolled in LETS phase III trial comparing first-line S-1/carboplatin with paclitaxel/carboplatin and subjected to multiplex genotyping for 214 somatic hotspot mutations in 26 genes (LungCarta Panel) and 20 major variants of ALK, RET, and ROS1 fusion genes (LungFusion Panel) with the Sequenom MassARRAY platform.
|
24810493 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In fact, TRAP1: i) contributes to the tumor's switch to aerobic glycolysis through the inhibition of succinate dehydrogenase, the complex II of the mitochondrial respiratory chain; ii) is part of a pro-survival signaling pathway aimed at evading the toxic effects of oxidants and anticancer drugs and protects mitochondria against damaging stimuli via a decrease of ROS generation; iii) controls protein homeostasis through a direct involvement in the regulation of protein synthesis and protein co-translational degradation.
|
24990602 |
2014 |